查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878834

出血性疾病藥物市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類型、疾病類型、配銷通路、最終用戶、地區和競爭格局分類，2020-2030年預測

Bleeding Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Disease Type, By Distribution Channel, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球出血性疾病藥物市場規模為60.3億美元，預計2030年將以6.78%的複合年成長率成長至89.4億美元。出血性疾病藥物是指透過促進血栓和減少出血來治療由血液凝固障礙引起的疾病（例如血友病和血管性血友病）的藥物。這些疾病在全球範圍內日益普遍，以及診斷方法的進步使得早期檢測成為可能，這些因素顯著推動了市場成長。此外，重組和非因子療法（包括基因療法的開發）的持續創新也提高了治療效果。

市場概覽
預測期 2026-2030
2024年市場規模 60.3億美元
2030年市場規模 89.4億美元
2025-2030年複合年成長率 6.78%
成長最快的細分市場 血漿衍生凝血因子濃縮物
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球出血性疾病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型分類（血漿來源凝血因子濃縮物、重組凝血因子濃縮物、去氨加壓素、抗纖溶藥、纖維蛋白密封劑、其他）
    • 依疾病類型（血友病A、血友病B、血管性血友病、其他）
    • 按配銷通路（醫院藥房、零售藥房、線上）
    • 按最終使用者（醫院、血友病治療中心、研究機構、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美出血性疾病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲出血性疾病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區出血性疾病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲出血性疾病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲出血性疾病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球出血性疾病藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Bayer AG
  • Grifols SA
  • Pfizer Inc.
  • Octapharma AG
  • Ferring International Center SA
  • Sanofi SA
  • Baxter International Inc.
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Novo Nordisk A/S

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 7331

The Global Bleeding Disorders Drugs Market, valued at USD 6.03 Billion in 2024, is projected to experience a CAGR of 6.78% to reach USD 8.94 Billion by 2030. Bleeding disorders drugs are pharmaceutical interventions designed to manage conditions stemming from impaired blood coagulation, such as hemophilia and von Willebrand disease, by facilitating clot formation and mitigating bleeding episodes. The market's expansion is significantly propelled by the increasing global prevalence of these disorders and advancements in diagnostic methodologies that enable earlier detection. Furthermore, continuous innovation in recombinant and non-factor therapies, including the development of gene therapies, enhances treatment efficacy.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.03 Billion
Market Size 2030USD 8.94 Billion
CAGR 2025-20306.78%
Fastest Growing SegmentPlasma-Derived Coagulation Factor Concentrates
Largest MarketNorth America

Key Market Drivers

The increasing global prevalence of bleeding disorders represents a primary driver for the expansion of the bleeding disorders drugs market. Conditions such as hemophilia and von Willebrand disease affect a substantial patient population, creating an ongoing demand for effective therapeutic interventions. Enhanced diagnostic capabilities, alongside greater public and medical professional awareness, contribute to a higher rate of diagnosis, subsequently increasing the number of identified patients requiring treatment. This expanding patient base directly translates into a heightened need for existing and novel pharmaceutical products designed to manage these complex conditions.

Key Market Challenges

The elevated cost of advanced therapies, particularly gene therapies and extended half-life products, significantly impedes the expansion of the global bleeding disorders drugs market. These high costs directly restrict patient access, especially in low-income regions where the economic burden of treatment is substantial. This limitation is compounded by less developed healthcare infrastructure and inadequate reimbursement policies prevalent in these areas, making it challenging for healthcare systems to procure and provide these expensive yet effective treatments.

Key Market Trends

The shifting treatment paradigm towards gene therapies represents a significant transformation in the global bleeding disorders drugs market. These advanced therapies aim to offer potentially curative or long-lasting solutions, moving beyond the traditional need for frequent factor infusions. This shift dramatically alters disease management by providing sustained endogenous factor production, thereby enhancing patient quality of life and reducing the long-term treatment burden. According to the World Federation of Hemophilia's 2024 Annual Report, the organization formally began tracking these novel treatments by enrolling its first patient in the Gene Therapy Registry in 2024, signaling a concentrated effort by industrial associations to monitor their real-world impact

Key Market Players

  • Bayer AG
  • Grifols S.A.
  • Pfizer Inc.
  • Octapharma AG
  • Ferring International Center S.A.
  • Sanofi S.A.
  • Baxter International Inc.
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Novo Nordisk A/S

Report Scope:

In this report, the Global Bleeding Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bleeding Disorders Drugs Market, By Drug Type:

  • Plasma-derived Coagulation Factor Concentrates
  • Recombinant Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants
  • Others

Bleeding Disorders Drugs Market, By Disease Type:

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

Bleeding Disorders Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

Bleeding Disorders Drugs Market, By End User:

  • Hospitals
  • Hemophilia Treatment Centers
  • Research Institutes
  • Others

Bleeding Disorders Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Bleeding Disorders Drugs Market.

Available Customizations:

Global Bleeding Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bleeding Disorders Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others)
    • 5.2.2. By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)
    • 5.2.4. By End User (Hospitals, Hemophilia Treatment Centers, Research Institutes, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Bleeding Disorders Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Disease Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bleeding Disorders Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Disease Type
        • 6.3.1.2.3. By Distribution Channel
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Bleeding Disorders Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Disease Type
        • 6.3.2.2.3. By Distribution Channel
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Bleeding Disorders Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Disease Type
        • 6.3.3.2.3. By Distribution Channel
        • 6.3.3.2.4. By End User

7. Europe Bleeding Disorders Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Disease Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bleeding Disorders Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Disease Type
        • 7.3.1.2.3. By Distribution Channel
        • 7.3.1.2.4. By End User
    • 7.3.2. France Bleeding Disorders Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Disease Type
        • 7.3.2.2.3. By Distribution Channel
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Bleeding Disorders Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Disease Type
        • 7.3.3.2.3. By Distribution Channel
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Bleeding Disorders Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Disease Type
        • 7.3.4.2.3. By Distribution Channel
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Bleeding Disorders Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Disease Type
        • 7.3.5.2.3. By Distribution Channel
        • 7.3.5.2.4. By End User

8. Asia Pacific Bleeding Disorders Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Disease Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bleeding Disorders Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Disease Type
        • 8.3.1.2.3. By Distribution Channel
        • 8.3.1.2.4. By End User
    • 8.3.2. India Bleeding Disorders Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Disease Type
        • 8.3.2.2.3. By Distribution Channel
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Bleeding Disorders Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Disease Type
        • 8.3.3.2.3. By Distribution Channel
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Bleeding Disorders Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Disease Type
        • 8.3.4.2.3. By Distribution Channel
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Bleeding Disorders Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Disease Type
        • 8.3.5.2.3. By Distribution Channel
        • 8.3.5.2.4. By End User

9. Middle East & Africa Bleeding Disorders Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Disease Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Bleeding Disorders Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Disease Type
        • 9.3.1.2.3. By Distribution Channel
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Bleeding Disorders Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Disease Type
        • 9.3.2.2.3. By Distribution Channel
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Bleeding Disorders Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Disease Type
        • 9.3.3.2.3. By Distribution Channel
        • 9.3.3.2.4. By End User

10. South America Bleeding Disorders Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Disease Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Bleeding Disorders Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Disease Type
        • 10.3.1.2.3. By Distribution Channel
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Bleeding Disorders Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Disease Type
        • 10.3.2.2.3. By Distribution Channel
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Bleeding Disorders Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Disease Type
        • 10.3.3.2.3. By Distribution Channel
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bleeding Disorders Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayer AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Grifols S.A.
  • 15.3. Pfizer Inc.
  • 15.4. Octapharma AG
  • 15.5. Ferring International Center S.A.
  • 15.6. Sanofi S.A.
  • 15.7. Baxter International Inc.
  • 15.8. F. Hoffmann-La Roche Ltd
  • 15.9. Takeda Pharmaceutical Company Limited
  • 15.10. Novo Nordisk A/S

16. Strategic Recommendations

17. About Us & Disclaimer